Key Highlights
- Third-quarter Revenue of USD 3.1 million came from network validation rewards and coin locking services for Canton Strategic Holdings (NASDAQ:CNTN), against nothing a year earlier when it was still a biotech.
- An unrealised loss of USD 54.6 million on Canton Coin holdings produced a continuing-operations loss of USD 38.6 million, cushioned by a USD 15.3 million tax benefit.
- The total net loss reached USD 35.1 million compared with USD 2.1 million last year, after USD 3.5 million of income from discontinued operations linked to the Gravitas disposal.
- On September 30, 2026 the firm owned 3.83 billion Canton Coin, carried at USD 482.1 million, and USD 26.9 million in cash and equivalents accompanied that position.
Coin Revaluation Accounts for Most of the Quarter's Deficit
Canton Strategic Holdings (NASDAQ:CNTN) lodged its quarterly filing on November 16, 2026, covering the period ending September 30. Revenue reached USD 3.1 million, divided almost equally between USD 1.5 million of network validation income and USD 1.5 million of other income, chiefly locking services. Overhead rose 49% to USD 2.7 million with higher pay, insurance and digital asset expenses. The unrealised digital asset loss drove pre-tax results to a USD 53.9 million deficit, and a USD 15.3 million tax Credit then left continuing operations at a loss of USD 38.6 million. Interest income increased to USD 0.4 million, boosted by interest on the Gravitas note.
Pivot From Biotechnology Into a Canton Coin Treasury
Between 2022 and late 2025 the company worked on therapies for inflammatory and immune conditions. In November 2025 it changed course toward holding and deploying Canton Coin while operating node infrastructure on the Canton Network, supported by private placements and a January 2026 offering. The biotech unit Gravitas changed hands on July 17, 2026 in exchange for a Promissory Note bearing payment-in-kind interest at 15%, with possible milestone payments of as much as USD 3.0 million. The company retained a bispecific antibody oncology effort, and the purchaser prepaid USD 1.1 million of the note in October, producing a gain of USD 3.7 million.
Validator Weight, Cost Basis and a USD 285.9 Million Equity Window
Active Super Validator weight increased to 6.5 in the quarter, with a further 8.5 logged but not yet eligible for minting. Management projects total validator weight could climb to 15.0 by the first quarter of 2028 if milestones are achieved. Nine-month remeasurement losses on coin holdings totalled USD 93.4 million. The cost basis of the 3.83 billion coins is USD 597.6 million, above their fair value. USD 285.9 million remains usable under the at-the-market deal signed in March 2026, while a buyback approved in June 2026 carries no duty to repurchase.
Where Things Stand
A USD 54.6 million unrealised loss on Canton Coin holdings accounts for the quarter. Canton Strategic Holdings (NASDAQ:CNTN) posted sales of USD 3.1 million while overhead reached USD 2.7 million, so by calculation operations were roughly break-even before the markdown. The markdown is what carried the figure down to a USD 35.1 million net loss. Coin Fair Value is USD 482.1 million, under the USD 597.6 million cost basis. Upcoming signals include more Super Validator weight, Demand for locking services and any draw on the funding agreement. Investors should judge the stock on coin prices as much as on operations.

_11_18_2026_16_06_39_204115.jpg)




Please wait processing your request...